Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J988- Other specified respiratory disorders
Conditions
Interventions
Intervention1: Niclosamide 2000 mg orally Plus Standard of Care: Niclosamide 2000 mg orally Plus Standard of Care
Treatment Duration for 07 Days
Control Intervention1: Standard Of Care: Standard Of Ca
Sponsors
Laxai Life Sciences Pvt Ltd
Council Of Scientific And Industrial Research Indian Institute Of Chemical Technology CSIRIICT
Eligibility
Inclusion criteria
Inclusion criteria: Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized, or practicing a reliable method of birth control during the duration of the study) patients with ages ranging from 18 to 65 years (both inclusive). Clinically stable condition for at least 6 months before enrollment. Confirmed diagnosis of moderate COVID-19 symptoms demonstrated by: Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens. Presence of dyspnea and/or hypoxia, fever, cough, including SpO2 24 and Signs of pneumonia (lung injury/lung involvement) confirmed by Chest X-Ray at the time of study entry. Disease severity score between Grade 4 to 5 on the WHO 9-point ordinal scale & patient requires hospitalization for management of the disease. Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2 via RT-PCR test. Able to take oral tablets at the time of study entry and agree not to participate in any other study for duration of participation in this study. Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from a legally acceptable representative (LAR).
Exclusion criteria
Exclusion criteria: Subjects will be excluded from the study for any of the following reasons: Subjects with known allergy or hypersensitivity to Niclosamide or any of its components. Patients who have previously had a disease severity score of 6 or 7 on the WHO 9-point ordinal scale. Evidence of severe or critical illness, defined by at least 1 of the following: Respiratory failure requiring at least 1 of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure Shock (defined by systolic blood pressure (BP) OR Multi-organ dysfunction/failure Subjects with Chronic liver disease (Child-Pugh class B or C) and chronic renal disease (GFR Renal dysfunction [Serum Creatinine > 2.5 times of ULN or calculated creatinine clearance 3times ULN & AST/ALT >5times ULN]. Subjects with oxygen saturation (SpO2) �90%. Respiration Rate �30 breaths per minute at the time of enrolment. History of refractory nausea, vomiting, or chronic gastrointestinal disorders, inability to swallow the study drug, or having undergone extensive bowel resection which may affect adequate absorption of study medications. Inability to swallow tablets (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug). Patients who require IL-6 inhibitors for management of inflammation at the time of study entry. Female subjects who are pregnant or involved in breastfeeding. Subject was using adrenocorticosteroids (except topical or inhaled preparations) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists, or interleukin receptor blockers) within one week prior to study entry. Subject has a serious chronic disease (e.g., human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus, cancer requiring chemotherapy within the preceding 6 months, unstable cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days. Has a history of alcohol or drug abuse in the previous 6 months. Subject has a psychiatric disease that is not well controlled where controlled is defined as stable on a regimen for more than one year. Subject already treated with another COVID 19 therapy but has relapsed with a positive diagnosis. Hospital discharge is anticipated in �24 hours. Anticipated transfer to another hospital which is not a study site within 72 hours. Participated in any other clinical trial or taken an investigational drug within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Clinical Improvement of 2-points on WHO 8-Point Ordinal Scale Timepoint: Baseline, Day 03, Day 05, Day 07, Day 14, Day 21 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures for this study will include: Time to respiratory viral clearance Improvement in lung injury on Chest X-Ray Other outcome measures for this study will include: All-cause mortality Timepoint: Time frame : 3, 7, 10, 14 days Time frame: Baseline, 14, 21 days Time frame: 21 days | — |
Countries
India
Contacts
Public ContactDr R M Chhabra
Insignia Clinical Services Pvt. Ltd.
Outcome results
None listed